Skip to main content
Premium Trial:

Request an Annual Quote

Epitome Wins $500K SBIR from NSF to Develop Phosophoprotein Antibody Array

NEW YORK, Oct. 17 (GenomeWeb News) - Epitome Biosystems said today that it has received a two-year, $500,000 Phase II Small Business Innovation Research grant from the National Science Foundation to support the development of an antibody array that will measure phosphoproteins from three cell signaling pathways.


The award follows a Phase I SBIR that the company received in May 2004 to demonstrate feasibility of its EpiTag technology platform for phosphoprotein analysis. During this phase of the award, the company said that it developed high-affinity antibodies for peptide tags identified for proteins in the MapK signaling pathway, and used the antibodies in an array format to measure protein phosphorylation.


Epitome said that the new award will enable it to develop commercial products with expanded array content to encompass three cell signaling pathways.


For further details about Epitome's technology and its commercialization plans, see this week's ProteoMonitor.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.